Fig. 2From: Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatmentCrizotinib PFS of patients from the 1-CRZ group, the 1-PP group and the N1-PP groupBack to article page